TILE

Analyst Note: TILE (Interface, Inc.)

Date: 2026-06-20 Event Date: 2026-06-20

1. Structural Readiness

State: Active.

The setup has transitioned from a "forming" phase to a "confirmed" phase. The price action has successfully cleared the consolidation structure, firing the breakout signal.

• Conservative Entry: $30.38
• Current Price: $32.56
• Extension: +7.2% above conservative entry.
• Breakout Level: The breakout occurred as price moved decisively above the consolidation range, currently trading at $32.56.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led. As of 2026-06-20, there is no named secular thesis attached to this specific setup. The conviction for this trade is derived entirely from the structural quality of the "Coil" formation and the immediate business fundamentals reported in the most recent earnings cycle. We are not assigning a macro narrative (e.g., "Green Transition Leader" or "Office Rebound") to this trade; rather, we are judging the name strictly on the strength of the setup execution and the tangible evidence of order growth and backlog expansion provided in the Q1 2026 data.

3. Business Fundamentals

Company Overview: Interface, Inc. is a global flooring solutions company offering an integrated portfolio including carpet tile, luxury vinyl tile (LVT), nora® rubber flooring, and FLOR® premium area rugs. The company serves corporate office, education, healthcare, public buildings, retail, transportation, and residential living segments.

Operational Evidence (as of May 2026):

• Order Growth: Consolidated currency-neutral orders increased 8% year-over-year in Q1 2026. Global billings were up 16%, showing broad-based growth.
• Backlog Strength: The backlog was strong at the end of the quarter, up 18% year-to-date. As of April 27, 2026, the consolidated backlog of unshipped orders stood at approximately $256.6 million, up from $222.8 million at the start of the fiscal year (Feb 2, 2026).
• Segment Performance: Sales increases were driven by corporate office, public buildings, healthcare, and retail. Specifically, net sales in the EAAA (Europe, Africa, Asia, Australia) region increased 15.2% versus the comparable period in 2025. Nora rubber billings were up 16%, and healthcare global billings were up 11%.
• Guidance & Margins: Management guided for full fiscal year 2026 net sales of $1.45 billion to $1.48 billion with an adjusted gross profit margin of approximately 38.8% to 39%.
• Strategic Initiatives: Management expects a new strategic initiative to begin contributing to growth in the fourth quarter of 2026.
• Sustainability: Over 50% of materials in products are recycled or bio-based, the highest in commercial flooring.

Headwinds Cited by Management: Management explicitly anticipates that Q2 and the remainder of fiscal 2026 will be impacted by higher raw material costs, higher energy costs, and higher costs to procure LVT products amid increased global macro-economic uncertainty. They also cited geopolitical factors (Russia-Ukraine, Middle East conflicts), trade policies, and tariffs as potential adverse factors.

4. Archetype and Conviction

Archetype: Growth Leader The name fits the "Growth Leader" archetype based on the evidence of accelerating order books, double-digit billing growth in key segments, and a robust backlog that provides visibility into future revenue. The 18% year-to-date backlog increase is a primary structural indicator of this growth trajectory.

Conviction Stack:

• Thesis Strength: Moderate (Tactical only; no macro tailwind assigned).
• Evidence Quality: High. The evidence block is dense with specific, quantitative data points from both earnings transcripts and SEC filings dated within the last month.
• Structural Quality: High. The ATR metrics (2.6% at breakout, 3.3% current) fall within the "productive" range, indicating a healthy volatility profile for a small-cap setup. The "Coil" structure has successfully resolved to the upside.
• Rerating Potential: The combination of strong backlog growth (18% YTD) and a clear path to margin expansion (targeting ~39% gross margin) suggests the market may be re-rating the stock based on the execution of the strategy, despite the acknowledged cost headwinds.

5. Invalidation, Strengthening, and Gaps

Invalidation Triggers:

• Fundamental: A significant miss on the Q2 2026 revenue guidance or a sharp contraction in the backlog below the $256.6 million level reported in April.
• Macro: Escalation of the geopolitical conflicts or trade policies cited by management that materially disrupts the supply chain or demand in key regions (EAAA, Healthcare).

Strengthening Triggers:

• Technical: A sustained move higher with volume, confirming the breakout.
• Fundamental: Confirmation that the "new strategic initiative" mentioned in E4 is delivering results ahead of the Q4 2026 timeline, or that the 16% global billing growth accelerates in Q2.
• Margin: Evidence that the company is successfully passing through the higher raw material and energy costs without compressing the targeted 38.8%-39% gross margin.

Evidence Gaps:

• Q2 Specifics: While management *anticipates* revenue growth in Q2 (E10), the actual Q2 results are not yet available as of the June 20, 2026 date. We are relying on Q1 momentum and management's forward-looking statements.
• Cost Impact Quantification: Management cites higher costs (E11) but does not provide a specific quantitative estimate of the margin impact in the provided evidence, leaving the net effect on the 39% margin target as a management expectation rather than a confirmed outcome.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key risks: Management anticipates higher raw material, energy, and LVT procurement costs impacting Q2 and full-year margins; Geopolitical conflicts and trade policies pose adverse demand risks; Q2 results not yet verified against Q1 momentum. Sizing hint: Position size should reflect the "medium" confidence and the tactical nature of the setup; standard small-cap volatility sizing applies. Expected path: Management expects revenue growth in Q2 and the full year to continue, with a new strategic initiative beginning to contribute in Q4 2026; structural implications suggest the backlog will convert to revenue, supporting the growth narrative despite cost headwinds. Expected horizon: 3 to 6 months, aligning with the Q2 earnings release and the trajectory of the backlog conversion.